Efficient myoblast expansion for regenerative medicine use by Jarocha, Danuta et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  34:  83-91,  2014
Abstract. Cellular therapy using expanded autologous 
myoblasts is a treatment modality for a variety of diseases. In 
the present study, we compared the commercial skeletal muscle 
cell growth medium-2 (SKGM-2) with a medium designed 
by our group for the expansion of skeletal myoblasts. The use 
of an in-house medium [DMEM/F12 medium supplemented 
with EGF, bFGF, HGF, insulin and dexamethasone (DFEFH)] 
resulted in a greater number of myoblast colonies (>50%) and a 
3-, 4- and 9-fold higher proliferation rate, eventually resulting 
in a 3-, 7- and 87-fold greater number of cells at the 1st, 2nd 
and 3rd passage, respectively, compared with the cells grown 
in SKGM-2 medium. The average CD56 expression level was 
higher in the myoblasts cultured in DFEFH than in those 
culturd in SKGM-2 medium. At the 3rd passage, lower expres-
sion levels of myostatin and considerably higher expression 
levels of myogenin were observed in the cells that were grown 
in DFEFH medium. The results of our study indicated that 
myoblasts cultured in both medium types displayed fusogenic 
potential at the 3rd passage. Furthermore, it was shown that cells 
cultured in DFEFH medium created myotubes with a consider-
ably higher number of nuclei. Additionally, we observed that 
the fusion potential of the cells markedly decreased with the 
subsequent passages and that the morphology of the myoblasts 
differed between the 2 cultured media. Our data demonstrate 
that culture in the DFEFH medium leads to an approxi-
mately 90-fold greater number of myoblasts, with improved 
morphology and greater fusion potential, compared with 
culture in the commercial SKGM-2 medium.
Introduction
Autologous myoblasts that have expanded from satellite cells 
isolated from muscle biopsy samples constitute the basis 
for cell replacement therapies in regenerative medicine for 
the treatment of urinary incontinence, ischemia-damaged 
myocardium or Duchenne muscular dystrophy. Clinical 
reports on autologous muscle-derived cells (MDCs) used for 
the treatment of either ischemia-damaged myocardium or 
urinary incontinence in humans have demonstrated the depen-
dency of the therapeutic effect on the number of injected cells, 
with >1x108 myoblasts required to obtain significant results or 
improved symptoms (1-3). These observations indicate that 
this treatment strategy may require a high number of compe-
tent cells to obtain a sufficient therapeutic effect.
Satellite cells remain in a quiescent state in uninjured tissue. 
Minor damage or injury to the tissue stimulates the release of 
hepatocyte growth factor (HGF) and basic fibroblast growth 
factor (bFGF) from injured myofibers (4,5). HGF activates 
satellite cells and causes them to enter the cell cycle, proliferate, 
differentiate and fuse to regenerate injured muscle fibers (4). 
HGF has been shown to be the only growth factor capable of 
activating satellite cells in in vitro primary culture (6-8). bFGF 
has been shown to enhance myoblast proliferation by increasing 
cyclin-D1 mRNA expression between 4 and 8 h post-induction 
with a return to initial levels by 32 h post-induction (9). Notably, 
bFGF has been reported to enhance the HGF-stimulated 
proliferation of myoblasts (10) and to repress the terminal 
differentiation of myoblasts (11). McGeachie and Grounds have 
shown in vivo the presence of dividing myoblasts up to 120 h after 
damage (12). However, this rate of proliferation is not maximal 
and can be increased in vitro by the addition of members of 
the fibroblast growth factor family (13,14). Epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF) and tumor 
growth factor (TGF)-β have also been reported to enhance 
myoblast proliferation in vitro (15-17). When proliferating 
myoblasts must withdraw from the cell cycle to differentiate, 
growth factors, such as HGF and bFGF, which stimulate cell 
cycle progression, regulate the activity of myogenic regulatory 
transcription factors, such as MyoD, myogenic factor 5 (Myf5), 
myogenin and myogenic regulatory factor (MRF)4, that have 
been shown to control the specification and differentiation of 
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the muscle lineage (18). During regeneration, activated satel-
lite cells reportedly initially express either Myf5, MyoD or 
both (19,20). Myogenin is required for the differentiation of 
myoblasts (21); MRF4 is thought to be involved in the matura-
tion of myotubes (22).
Myostatin, a growth factor and a TGF-β superfamily 
member, is a specific negative regulator of skeletal muscle 
mass (23). This growth factor has been shown to play a role in 
regulating the activation, growth and self-renewal of satellite 
cells (24) and to inhibit the growth of myoblasts (25). Myostatin 
has also been shown to negatively regulate myogenic differ-
entiation by inhibiting the mRNA and protein expression of 
MyoD, Myf5, myogenin and myosin heavy chain 2A (MyHC-
2A) (26,27). MyHC-2A is one of 3 fast-type isoforms of a 
muscle contractile protein known as myosin heavy chain (28). 
In low seeding density cultures without supplemental growth 
factors, MyHC-2A mRNA expression has been shown to 
increase in parallel with a decrease in Myf5 and myogenin 
expression; this result indicates a correlation with phenotypic 
differentiation (29).
Initial in vitro experiments with muscle cell progenitor 
cultures have been performed in Ham's F10 or Ham's F-12 
media (30,31) and have also been performed in other media, 
such as Dulbecco's modified Eagle's medium (DMEM) (32,33). 
However, the use of these media results in a low number of 
cells. Published culture strategies aimed at increasing the 
number of obtained myoblasts have emphasized the impor-
tance of proteins used for flask covering, supplementation with 
various growth factors and different cell passaging strategies, 
as well as the effect of these variables on the kinetics and the 
proliferation potential of myoblast expansion (17,29,31,34-36). 
The effectiveness of EGF, FGF and PDGF growth factors in 
enhancing expansion capacity has also been reported (16,36). 
Thus, a higher number of myoblasts can be obtained using 
skeletal muscle cell growth medium (SKGM) (3,37) or 
DMEM with the addition of growth factors. A high propor-
tion of serum and non-confluent culture conditions have been 
shown to prevent myogenic differentiation (38). An automated 
culture system indicated that the optimal seeding density and 
attainable confluence was 1x103 cells/cm2 and 50% conflu-
ence, respectively (39). However, a recent study indicated that 
prolonged culture leads to an increased percentage of senes-
cent cells, a decreased ability of myoblasts to form myotubes 
and alterations in glucose and lipid metabolism (40).
In the present study, we compared the commercial medium, 
SkGM™-2 BulletKit™Medium (SKGM-2; current version 
of the no longer available SKGM), with a medium designed 
by our group [DMEM/F12 medium supplemented with EGF, 
bFGF, HGF, insulin and dexamethasone (DFEFH)]. The aim 
of this study was to seek the optimal large-scale expansion 
conditions of functional MDCs for regenerative medicinal use 
by comparing the expansion efficacy and the fusogenic poten-
tial of skeletal myoblasts in these 2 media.
We demonstrate culturing conditions that produce up to 
5x109 myoblasts, presenting fusogenic potential in 24 days. 
We also demonstrate that the number of myoblast colonies, 
the doubling time, the duration of the logarithmic growth 
phase, the number of expanded cells and the cell morphology 
strongly depend on culture conditions. Our results demon-
strated that the use of an in-house medium resulted in an 
approximately 100-fold greater number of cells of less 
differentiated morphology and higher fusion potential during 
3 passages compared with cells cultured in SKGM-2 medium. 
Additionally, we show that the expansion of myoblasts over 
23 generations results in a rapid decrease in the proliferation 
potential, and an increase in the doubling time, the appearance 
of vacuoles and the loss of the fusion potential of these cells.
Materials and methods
Muscle biopsy and primary cell culture. Deltoid muscle 
samples of approximately 0.2 g were acquired from women 
with stress urinary incontinence (20% available for the experi-
ments), aged over 50 years, by a needle biopsy performed under 
local anesthesia. Both institutional review board approval and 
informed consent from all participants were obtained prior 
to the biopsy procedure. All muscle biopsies were trans-
ported in phosphate-buffered saline (PBS) with antibiotics 
(PAA Laboratories GmbH, Goetzis, Austria) and stored at 
room temperature until processing, which was generally 
performed 2 h after the biopsy had been obtained. First, the 
muscle samples were rinsed in PBS and cleaned by removing 
adherent fat and tendon tissues using a scalpel. The muscle 
tissue was then cut into small sections and digested with 2 mg/
ml of collagenase 1A (Sigma-Aldrich, Seelze, Germany) for 
40 min at 37˚C, as previously described (33). Individual fibers 
were liberated by rigorous pipetting and were centrifuged at 
300 x g for 5 min. The pellet was resuspended in a small volume 
of PBS, was divided into 2 parts and was centrifuged again.
To compare the expansion efficacy of the SKGM-2 medium 
(Lonza, Walkersville, MD, USA) (formulated by combining 
SKBM™-2 Basal Medium, CC-3246 with the SkGM™-2 
SingleQuots™ kit, CC-3244) with that of the in-house 
medium, one-tenth of the muscle fibers was resuspended 
in SKGM-2 medium and another one-tenth was resus-
pended in the medium designed by our group: DMEM/F-12 
(PAA Laboratories GmbH) supplemented with dexametha-
sone, insulin (both from Sigma-Aldrich), 18% fetal bovine 
serum (FBS) (PAA Laboratories GmbH) and the growth 
factors, EGF, FGF (2) and HGF, (DFEFH). The muscle fibers 
were then transferred into 6-well plates coated with laminin 
(Sigma-Aldrich) to enable the released satellite cells to adhere 
to or migrate out of the muscle fibers. The plates were incu-
bated for 48 h in a humidified atmosphere containing 5% CO2. 
After 48 h, the medium with the muscle fragments that had 
not adhered to the plates was changed (P0) and the superna-
tant containing the muscle fibers was transferred into new 
laminin-coated wells (P1). After a further 48 h, the procedure 
was repeated and the medium in all wells was changed every 
3 days. At day 8 of culture, the number of colonies, defined as 
a cluster of at least 10 cells, was counted in wells P0 and P1 
and summarized.
Myoblast culture. The first passage was performed on day 11; 
the cells were passaged from a 6-well plate to a 25 cm2 flask, 
with a seeding density of 1,000 cells/1 cm2. The cells were 
cultured in SKGM-2 or DFEFH medium at 37˚C, 5% CO2 and 
95% humidity. The medium was changed twice a week. The 
cells were harvested after 7 days and reseeded again at the 
same density of 1x103 cells/1 cm2.
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Manual cell counts to assess myoblast number. Every 7 days, 
the cells were harvested for reseeding; the cell number was 
counted using a hematocytometer and a light microscope 
(Olympus, Tokyo, Japan).
RNA extraction and reverse transcription. Total RNA was 
extracted using an RNeasy mini kit (Qiagen, Valencia, CA, 
USA). The reverse polymerase transcription was performed 
using reverse transcription reagents (Roche/Applied Biosystems, 
Foster City, CA, USA) or M-MLV Reverse Transcriptase 
(Promega, Madison, WI, USA) according to the manufacturer's 
instructions.
Quantitative PCR. Myostatin, Myf5, myogenin and MYH2 
expression levels were determined by quantitative (real-time) 
PCR on an ABI PRISM 7300 Sequence Detection System 
(Applied Biosystems) using a commercially available TaqMan 
PCR master mix. Spanning an exon junction, the TaqMan 
probes used for this analysis were as follows: myostatin 
(Hs00976237_m1), Myf5 (Hs00271574_m1), myogenin 
(Hs01032275_m1), and MYH2 (Hs00430042_m1), all from 
Applied Biosystems. The 2-ΔΔCT method was used to quantify 
the relative expression levels of the genes. The mRNA expres-
sion levels for all samples were normalized to the housekeeping 
gene, GAPDH.
Purity evaluation. The percentage of CD56+ cells was 
assessed using monoclonal anti-CD56-APC antibodies 
(BD Biosciences, San Jose, CA, USA) and cytofluorymetric 
evaluation on a FACSCalibur with a CellQuest analysis software 
(BD Biosciences Immunocytometry Systems).
Evaluation of the fusion potential of MDCs. To evaluate fusion 
potential, the cells were seeded in 96-well plates in duplicate; 
once the cells reached 80% confluence, the culture medium 
was changed to DMEM with 2% FBS and 25 μmol/l insulin, 
as previously described (40). The medium was changed twice 
a week. On day 11, the cells were fixed and stained with 
Wright's eosin methylene blue solution (Merck, Darmstadt, 
Germany). The number of nuclei in the 6 largest myotubes was 
counted in each well.
Statistical analysis. Statistical analysis was performed using a 
one- or two-tailed paired Student's t-test with Microsoft Excel; 
a value of p<0.05 was considered to indicate a statistically 
significant difference.
Results
Growth of primary myoblast colonies. To isolate the satel-
lite cells, the digested muscle tissue was seeded in culture 
medium on laminin-coated plates to enhance the adherence of 
satellite cells, as previously described (34). At the beginning 
of myoblast expansion, the same volume of digested muscle 
tissue was seeded in single wells of a laminin-coated 6-well 
plate in 2 types of medium, SKGM-2 and DFEFH. On day 6, 
the number of growing myoblast colonies was counted using 
an inverted microscope. As shown in Fig. 1A, culture in the 
DFEFH medium resulted in an average of 41 myoblast colonies 
compared with 27 myoblast colonies obtained with culture in 
the SKGM-2 medium. Thus, a statistically significant increase 
in the colony number was observed.
Proliferation rate and doubling time of satellite cells. The cells 
were passaged for the first time after 11 days, when the colonies 
had begun to be more associated with each other. As shown in 
Fig. 1B, culture in DFEFH medium resulted in 0.15x106 cells, 
a number which was approximately 3-fold higher than that of 
the cells (0.05x106 ) cultured in SKGM-2 medium (Fig. 1B). 
The cells were seeded into 25 cm2 culture flasks with the same 
density, i.e., 1x103 cells/cm2. The following passages were 
performed once one of the cultures reached approximately 
75% confluence, after approximately 6-7 days. In 2 further 
passages, the cells cultured in DFEFH medium required less 
time to obtain passaging confluence; consequently, a higher 
number of cells was obtained with this medium. After the 
2nd passage, the difference in the number of cells obtained 
was even higher, i.e., 1.55x106 cells were obtained with DFEFH 
medium, a number which was approximately 4-fold higher 
than that of cells (0.4x106) obtained by culture in SKGM-2 
medium. Finally, after the 3rd passage, the greatest differ-
ence was observed, with 2.6x106 cells obtained from DFEFH 
medium cultures, that is, a number which was approximately 
9-fold higher than that of cells (0.29x106) cultured in SKGM-2 
medium. The differences at passages 2 and 3 were statistically 
significant (p<0.05). Cumulative cell numbers, which could 
be finally achieved by seeding all the cells at each passage, 
were calculated. Cell culture in DFEFH medium obtained 
5.84x108 myoblasts, while culture in SKGM-2 obtaiend only 
6.7x106 myoblasts (Fig. 1C).
In brief, our results indicated that culture in DFEFH 
medium, starting with the same volume of digested tissue as 
with culture in SKGM-2 medium, produced a greater number 
(100-fold) of myoblasts compared with culture in SKGM-2 
medium. The doubling times for the cells cultured in DFEFH 
medium were 21.5 and 30 h between passages 1 and 2 and 
between passages 2 and 3, respectively (Fig. 1D). The cells 
cultured in SKGM-2 medium had doubling times of 32.3 and 
60.3 h between passages 1 and 2 and between passages 2 and 3, 
respectively.
Only the cultures from the DFEFH medium were submitted 
to further passages; after the 3rd passage, the proliferation rate 
of the cultures considerably decreased and remained low until 
the end of the expansion phase at the 7th passage (Fig. 1E).
Expression of proliferation and differentiation markers by 
expanded myoblasts. The mRNA expression levels of the 
selected genes were investigated by quantitative PCR. The 
expression levels of the myostatin, Myf5, and myogenin genes 
were slightly lower at passage 3 than at passage 2, when the 
myoblasts were cultured in SKGM-2 medium (Fig. 2A). Similar 
results were observed for myoblasts cultured in DFEFH 
medium; the expression of the myostatin and Myf5 genes in 
myoblasts cultured in DFEFH medium was lower at passage 3 
than at passage 2. By contrast, the expression of myogenin was 
higher at passage 3 than at passage 2 for myoblasts cultured 
in DFEFH medium (Fig. 2A). Furthermore, a comparison of 
the gene expression levels between myoblasts expanded in the 
different media, but during the same passage indicated that 
myostatin expression was 25% lower at passage 2 and approxi-
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mately 3-fold lower in the cells cultured in DFEFH at passage 3. 
The expression of Myf5 was similar at both passage 2 and 
passage 3. For the cells cultured in DFEFH, myogenin expres-
sion was approximately 2-fold higher at passage 3 than at 
passage 2; this result was statistically significant (p<0.05). An 
analysis of the mRNA expression levels of myoblasts cultured 
in DFEFH medium from passage 2 up to passage 7 indicated 
that the myostatin and Myf5 expression levels decreased from 
passages 2 to 5. The myogenin expression levels increased 
by approximately 3-fold of those at the initial phase during 
expansion and then decreased by approximately 30% at the 
end of the expansion phase (Fig. 2B).
Morphological analysis of satellite cells in culture and 
MyHC-2A expression. The morphological aspects of 
myoblasts cultured in 2 different culture media are shown in 
Fig. 3A. The morphology of the adherent myoblasts differed 
between the 2 cultured media. At the beginning of the culture, 
after passage 1, the difference was subtle. All cells cultured in 
DFEFH medium were small and spindle-like, whereas some 
elongated cells in between the spindle-like cells appeared 
when the cells were cultured in SKGM-2 medium. After the 
2nd passage, the difference was considerable. Some elon-
gated cells appeared among the spindle-like cells cultured in 
DFEFH, but all the cells cultured in SKGM-2 medium became 
Figure 1. Effect of the culture medium on the number of myoblast colonies, the doubling time and expansion efficacy. Suspensions containing muscle fibers 
and single cells after collagenase digestion of muscle tissue from approximately 0.02 g of biopsy fragments were seeded on laminin-coated wells of a 6-well 
plate in skeletal muscle cell growth medium-2 (SKGM-2) or DFEFH medium (P0). After 48 h, supernatants were transferred into new wells (P1), fresh medium 
was added to P0, and the procedure was repeated after another 48 h. At day 8, the number of colonies, defined as at least 10 cells, was counted in P0 and P1 
and added. At day 11, the first passage was performed and the cells were counted. Cells were seeded at a density of 0.025x106/25 cm2 flask and passaged with 
a constant seeding density every 6-7 days until the 3rd passage. The cell number was counted and the doubling time was calculated at each passage. Cells 
expanded in DFEFH medium were cultured until passage 7, starting with the same seeding density of 0.025x106 cells/25 cm2 flask from passage 1 to the final 
passage. (A) The number of myoblast colonies obtained in different media on day 6, n=2 (2 different donors); *p<0.05. (B) The proliferation rate of myoblast 
expansion during passages 1-3, n=3 (3 different donors); *p<0.05. (C) The cumulative cells number, that could be obtained in SKGM-2 and DFEFH medium 
after 3 passages, n=3 (3 different donors); *p<0.05. (D) The doubling time of myoblasts cultured in different medias at passage 2 and 3, n=3 (3 different donors); 
*p<0.05. (E) The profile of the kinetics of myoblast proliferation in DFEFH medium, n=2 (2 different donors).
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elongated. This considerable difference in the morphology of 
the cells was retained after the 3rd passage.
All cells expressed MyHC-2A at both the 2nd and 
3rd passage. The myoblasts cultured in SKGM-2 medium had 
a constant, higher expression of MyHC-2A at both passages 
than those cells cultured in DFEFH (Fig. 3B).
Only the cells cultured in DFEFH medium were submitted 
to further passage. However, during subsequent passages, most 
of the cells cultured in DFEFH medium also became elongated 
and vacuolated (data not shown).
Purity of myoblast cultures. The average expression of the 
CD56 antigen in myoblasts cultured in DFEFH medium was 
70% (60-80%), while in myoblasts cultured in SKGM-2, it was 
55% (20-90%) (data not shown).
Fusogenic capacity. The formation of myotubes depends 
entirely on the capacity of the cells to fuse with each other (29). 
In this study, after the 3rd passage, myoblasts cultured in both 
types of culture medium had the potential to fuse (Fig. 4A). 
The average number of nuclei in the 12 randomly selected 
myotubes was considerably higher for the myoblasts cultured 
in DFEFH medium (Fig. 4B). For the cells cultured in DFEFH 
medium, the effect of culture time on fusion potential was also 
examined. We observed that the fusion potential of the cells 
markedly decreased with the increasing number of passages, 
Figure 2. Effect of culture medium on the expression of myogenic genes in cultured myoblasts. Myoblasts were cultured in skeletal muscle cell growth 
medium-2 (SKGM-2) and DFEFH medium to passage 3. RNA was isolated from the cells at passages 2 and 3, reverse transcribed into cDNA and the expres-
sion of myogenic genes was assessed through quantitative analysis. Additionally, cells cultured in DFEFH medium were subjected to higher passages, and the 
expression of genes was assessed in a similar manner. (A) The expression of mRNA for myostatin, MYF-5, and myogenin genes of human skeletal myoblasts 
cultured in different medias at passages 2 and 3, n=2 (2 different donors); *p<0.05. (B) The expression of mRNA for myostatin, MYF-5, and myogenin genes 
of human skeletal myoblasts cultured in DFEFH and subjected to further passages, n=2 (2 different donors).
Figure 3. Morphology of myoblasts cultured in different media. Myoblasts were cultured in skeletal muscle cell growth medium-2 (SKGM-2) and DFEFH 
medium to passage 3. The morphology of the cells was examined before every passage using an inverted microscope. RNA was isolated from the cells at 
passages 2 and 3, reverse transcribed into cDNA and the expression of the MYHC-2A gene was assessed through real-time analysis. (A) Comparison of the 
morphology of myoblasts cultured in SKGM-2 and DFEFH medium at passages 1, 2 and 3. Representative results of 2 independent experiments are shown. 
(B) Comparison of MYHC-2A gene expression in myoblasts cultured in SKGM-2 and DFEFH medium at passages 2 and 3, n=2 (2 different donors).
JAROCHA et al:  EFFICIENT MYOBLAST EXPANSION88
and after passage 5, the fusion potential was very low (Fig. 4C). 
Moreover, the average number of nuclei in the 12 randomly 
selected myotubes was considerably lower at passages 4 and 5, 
in comparison with passage 3 (Fig. 4D).
Discussion
Myoblasts cultured from small muscle biopsies constitute 
the basis for evolving cell replacement therapies. Clinical 
reports on the use of myoblasts for cardiac indications (2,3) 
and urinary incontinence (1,41) indicate that a high number 
of cells (≥1x108) is required to obtain therapeutic effects or 
to improve patient symptoms. Thus, the in vitro culture of 
myoblasts for clinical use aims at obtaining the number of 
myoblasts with differentiation and fusion potentials that will 
be sufficient and will be able to regenerate damaged muscle. 
Culturing myoblasts is challenging as differentiation and 
myotube formation reduce their ability to grow.
A low-density passaging strategy (1x103cells/cm2) has 
been demonstrated to be the most appropriate for prefer-
able myoblast culture achievement (39). In this study, The 
commercially available SKGM-2 medium, containing EGF, 
was compared with DFEFH medium designed by our group, 
containing EGF, HGF and FGF growth factors.
Our resuls revealed that a) a higher number of satellite cells 
became activated in the in-house medium, b) their daughter 
myoblasts had a shorter doubling time and c) their loga-
rithmic growth phase lasted longer than those cells cultured 
in the commercial medium, SKGM-2. The higher number of 
myoblast colonies observed in DFEFH medium (Fig. 1A) may 
indicate that some of the satellite cells present in the muscle 
biopsy sample may remain inactivated and may be lost when 
cultured in SKGM-2 medium. DFEFH medium, in contrast 
to SKGM-2 medium, contained an addition of HGF, shown 
to be the only factor able to activate these cells in vivo and 
in vitro (4,6,7,42). During in vitro isolation, mechanical disrup-
tion precedes enzymatic digestion. The HGF released during 
this step may not be sufficient for the activation of all satellite 
cells; thus, the addition of this activating growth factor may 
be beneficial for the activation of a higher number of satellite 
cells.
There was an almost 3-fold higher proliferation rate at 
the first passage in the DFEFH medium than in the SKGM-2 
medium (Fig. 1B), resulting from a greater number (1.6-fold) 
of colonies, indicating the more rapid growth of the cells in 
DFEFH medium. The more rapid growth of cells in the DFEFH 
medium may be a result of stronger proliferation stimulation 
and/or differentiation prevention. Thus, the proliferation 
rate of myoblasts obtained by the stimulation of EGF alone 
in SKGM-2 medium can be enhanced by the stimulation of 
EGF combined with bFGF and HGF growth factors present in 
DFEFH medium. We hypothesized that the mechanism respon-
sible for the higher proliferation rate in DFEFH medium may 
be the result of two additional growth factors, HGF and bFGF. 
Both HGF and bFGF, present in DFEFH medium, have been 
shown to increase the in vitro proliferation of satellite cells. 
HGF influences the cells by accelerating cyclin-D1 expression 
and causing an earlier entry of the cells into the cell cycle (6), 
while bFGF influences the cells through the stimulation of 
cyclin-D1 expression (9). Additionally, FGF has been shown 
to prevent the terminal differentiation of expanded myoblasts 
through the suppression of MyHC-2A expression (8,11). The 
Figure 4. Fusion potential of cultured myoblasts in different media. After passage 3, cells cultured in 2 different media were seeded in duplicate into 96-well 
plates, and when 80% confluence was obtained, the culture medium was switched to fusion medium [Dulbecco's modified Eagle's medium (DMEM), 2% fetal 
bovine serum (FBS), 25 μmol/l insulin] and changed every 3 days. After 11 days, cells were fixed and stained with Wright's eosin methylene blue solution. 
The number of nuclei in the 6 largest myotubes was counted in each well. Additionally, cells cultured in DFEFH medium were subjected to higher passages 
and their fusogenic potential was assessed in a similar manner. (A) Comparison of the fusogenic potential of myoblasts cultured in skeletal muscle cell growth 
medium-2 (SKGM-2) and DFEFH medium at passage 3. Representative results of 2 independent experiments are shown. (B) The average number of nuclei in the 
largest myotubes created from myoblasts expanded in SKGM-2 and DFEFH medium at passage 3, n=2 (2 different donors); *p<0.05. (C) The fusion potential of 
myoblasts in prolonged cultured in DFEFH medium. Representative results of 2 independent experiments are shown. (D) The average number of nuclei in the 
largest myotubes created from myoblasts expanded in DFEFH medium at passages 3, 4 and 5, n=2 (2 different donors); *p<0.05. 
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  34:  83-91,  2014 89
addition of insulin to the DFEFH medium, which has been 
shown to have an anabolic effect on these cells, may be another 
factor (15).
During the following two passages, 4- and 9-fold higher 
proliferation rates were observed during the same culture time 
in DFEFH medium compared with SKGM-2 medium cultures, 
and each passage began with the same number of cells (Fig. 1B). 
The peak proliferation rate for myoblasts cultured in SKGM-2 
medium was observed at passage 2 after 17 days, while for 
myoblasts cultured in DFEFH, the peak proliferation rate was 
observed at passage 3 after 24 days. Different proliferation 
rates induced different (87-fold higher) cumulative numbers of 
myoblasts which were obtained from the same biopsy sample 
in the DFEFH culture. Furthermore, a doubling time of 21.5 
and 30 h for the 2nd and 3rd passages, respectively, for the cells 
cultured in DFEFH medium more closely resembled the 18.2 h 
observed in vivo following the activation of satellite cells in a 
previous study (42) than the doubling times of 32.3 and 60 h 
for the 2nd and 3rd passages, respectively, for cells cultured in 
SKGM-2 medium (Fig. 1D). The doubling time increased after 
the 2nd passage, at day 17, in both culture media, but for the cells 
cultured in DFEFH medium, the increase was approximately 
50%, whereas for the cells cultured in SKGM-2 medium, the 
increase was approximately 100%. This result indicates that the 
composition of DFEFH medium provides the stimulation for 
cell proliferation throughout the 17 days of culture, resulting 
in a doubling time similar to the in vivo proliferation rate of 
regenerating muscle cells. To summarize, during the 24 days 
of culture, myoblasts cultured in SKGM-2 medium underwent 
approximately 18 doublings, whereas myoblasts cultured in 
DFEFH medium underwent approximately 25 doublings. 
Additionally, the average purity of myoblasts cultured in 
DFEFH medium was greater and more convergent than that 
of those cultured in SKGM-2 medium. The high diversity of 
CD56 expression in myoblasts cultured in the previous version 
of SKGM-2, SKGM, has already been demonstrated (3).
In order to understand how these two culture media influ-
ence the endogenous regulation of myoblast proliferation and 
differentiation, we determined the mRNA expression levels of 
myostatin during regulation by the myogenic regulatory factors, 
Myf5 and myogenin, both in myoblasts cultured in DFEFH 
medium and in myoblasts cultured in SKGM-2 medium.
Molecular analysis revealed that the myostatin expression 
levels in both populations of cells were 1/4- and 3-fold lower 
in the cells cultured in DFEFH compared to those cultured 
in SKGM-2 at passages 2 and 3, respectively (Fig. 2A). This 
difference may be the result of bFGF, which has been shown to 
repress the expression of myostatin at the mRNA level, present 
in the DFEFH medium but absent in the commercial SKGM-2 
medium (43). This observation provides a more detailed expla-
nation of the shorter doubling time and the higher proliferation 
rate of the cells cultured in DFEFH medium as myostatin has 
been shown to block cell cycle progression by increasing p21 
expression, which blocks the release of E2F (25). A decrease 
in myostatin expression levels between passages 2 and 3 was 
observed in both media types. However, a greater decrease was 
observed in myostatin expression levels in DFEFH medium, 
indicating that the previously described negative autoregula-
tion of myostatin expression (44,45) may occur in order to 
unblock the differentiation of myoblasts (26,27).
Myf5 expression, confirming the myogenic phenotype of 
the cells, was detected at passages 2 and 3 in the cells cultured 
in both media types (46,20). As was expected, during the 
expansion of the cells, Myf5 expression levels decreased from 
passage 2 to 3 in both populations. An approximately 50% 
higher expression of Myf5 was observed at passage 2 in the 
cells cultured in DFEFH medium compared with those cultured 
in SKGM-2 medium. However, the higher expression level of 
Myf5 in cells that underwent two more doublings may be the 
result of a combination of growth factors that lower myostatin 
expression in these cells, as myostatin has been shown to 
inhibit the mRNA expression of Myf5 (26,27). At passage 3, 
the expression of Myf5 was similar in both populations of cells. 
Although the difference in myostatin expression was greater at 
passage 3, the cells cultured in DFEFH medium underwent four 
more doublings than those cells cultured in SKGM-2 medium; 
thus, fusion potential, lower myostatin expression levels and 
lower Myf5 inhibition may balance an expected decrease in 
Myf5 expression levels during subsequent doublings.
Parallel myogenin expression levels were observed in both 
populations of cells at the 2nd and 3rd passages, indicating 
that the cells differentiated into myoblasts (21,47). However, 
the myogenin expression levels in cells cultured in SKGM-2 
medium decreased between passages 2 and 3, indicating that 
the cells may be entering the early myocyte stage, whereas 
the myogenin expression levels in cells cultured in DFEFH 
medium increased between passages 2 and 3 and finally 
decreased at passage 7 (Fig. 2B), indicating that these condi-
tions may cause the cells to remain at the early differentiating 
myoblast stage much longer by decreasing myostatin expres-
sion levels (47).
Moreover, our data demonstrate that the culture medium 
composition influences the morphology of the expanded 
cells (Fig. 3A). Among the small spindle-like myoblasts 
cultured in SKGM-2 medium, single elongated cells appeared at 
passage 1, and most of the cells became elongated by passage 2, 
while the myoblasts cultured in DFEFH medium were still 
small, spindle-like cells at the second passage. This difference 
was still apparent at passage 3. However, the myoblasts cultured 
in DFEFH medium also became elongated and vacuolated at 
further passages, which correlated with a decreased prolif-
eration rate and an increased doubling time. The differences in 
morphology may be explained by the difference in the expression 
levels of the muscle contractile protein, MYHC-2A, which may 
be associated with phenotypic differentiation (29). MyHC-2A 
expression was 3-fold and 40% lower at passage 2 and 3, 
respectively, in myoblasts cultured in DFEFH medium than in 
those cells cultured in SKGM-2 medium (Fig. 3B). Different 
morphology could be also partly explained by different purity 
of myoblasts cultured in different media.
The differentiation potential of the cells in both media 
was compared at passage 3, when a substantial number of 
myoblasts could be achieved in both media types, showing 
similar  percentages  of  cells  undergoing  fusion. Ηowever, 
the myotubes created from myoblasts expanded in DFEFH 
medium contained considerably more nuclei after 11 days, 
which may be explained by the higher purity of the myoblasts 
culture. The differentiation potential of myoblasts expanded 
in DFEFH medium was also verified at further passages. 
A marked decrease in fusion potential was observed after 
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passage 3, leading to an almost complete lack of fusion at 
passage 5 and a considerable decrease of nuclei in created 
myotubes. The lack of fusion observed at further passages 
confirms the recent finding that, with  increasing passages, 
myoblasts become elongated cells with vesicles containing 
cytoplasm, their differentiation potential decreases and they 
acquire a different metabolic phenotype (40).
Our results confirm the earlier observations (2,3)  that a 
high number of myoblasts can be obtain in an in vitro setting.
However, our results also indicate a considerably higher, up 
to 5x109, expansion efficacy, in a considerably shorter time, 
i.e., 24 days [in contrast to 1x109 in 46 days after a 0.6-1.9 g 
biopsy (2), 3x108 in 18 days after a 2 g biopsy (3), or 3x108 in 
25 days after a 0.2 g biopsy], which may be caused by biopsy 
weight, growth factor composition and seeding density (39). 
We also confirm the findings of earlier reports showing that 
further expansion results in obtaining myoblasts that contain 
vacuoles and are unable to fuse (40).
The present study also suggests that conditions enabling 
the growth of up to 5x109 of myoblasts in 24 days present 
fusion potential in elderly patients. Additionally, it shows 
that the expansion of the cells over 23 generations results in 
the rapid decrease of proliferation potential, an increase in 
doubling time, the appearance of vacuoles in cells and the loss 
of fusion potential.
Setting standard conditions for the medium composition of 
myoblast expansion for clinical purposes by manipulating the 
intrinsic control of proliferation and differentiation may be of 
value. For the clinical transplantation of functionally compe-
tent cells for successful cell therapy and the unnecessary costs 
of prolonged cultures, the maximal number of doublings, 
rather than passages, that cells can undergo in in vitro condi-
tions should be set.
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